TY - JOUR
T1 - Strategies for Improving Enrollment of Diverse Populations with a Focus on Lipid-Lowering Clinical Trials
AU - Ogungbe, Oluwabunmi
AU - Grant, Jelani K.
AU - Ayoola, Adeoluwa Segilola
AU - Bansah, Eyram
AU - Miller, Hailey N.
AU - Plante, Timothy B.
AU - Sheikhattari, Payam
AU - Commodore-Mensah, Yvonne
AU - Turkson-Ocran, Ruth Alma N.
AU - Juraschek, Stephen P.
AU - Martin, Seth S.
AU - Lin, Michael
AU - Himmelfarb, Cheryl R.
AU - Michos, Erin D.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023/10
Y1 - 2023/10
N2 - Purpose of Review: We review under-representation of key demographic groups in cardiovascular clinical trials, focusing on lipid-lowering trials. We outline multilevel strategies to recruit and retain diverse populations in cardiovascular trials. Recent Findings: Barriers to participation in trials occur at the study, participant, health system, sponsor, and policy level, requiring a multilevel approach to effectively increase participation of under-represented groups in research. Increasing the representation of marginalized and under-represented groups in leadership positions in clinical trials can ensure that their perspectives and experiences are considered. Trial design should prioritize patient- and community-indicated needs. Summary: Women and individuals from racially/ethnically diverse populations remain under-represented in lipid-lowering and other cardiovascular clinical trials relative to their disease burden in the population. This limits the generalizability of trial results to the broader population in clinical practice. Collaboration between community stakeholders, researchers, and community members can facilitate shared learning about trials and build trust.
AB - Purpose of Review: We review under-representation of key demographic groups in cardiovascular clinical trials, focusing on lipid-lowering trials. We outline multilevel strategies to recruit and retain diverse populations in cardiovascular trials. Recent Findings: Barriers to participation in trials occur at the study, participant, health system, sponsor, and policy level, requiring a multilevel approach to effectively increase participation of under-represented groups in research. Increasing the representation of marginalized and under-represented groups in leadership positions in clinical trials can ensure that their perspectives and experiences are considered. Trial design should prioritize patient- and community-indicated needs. Summary: Women and individuals from racially/ethnically diverse populations remain under-represented in lipid-lowering and other cardiovascular clinical trials relative to their disease burden in the population. This limits the generalizability of trial results to the broader population in clinical practice. Collaboration between community stakeholders, researchers, and community members can facilitate shared learning about trials and build trust.
KW - Clinical trials
KW - Diversity
KW - Under-representation
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=85173127933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173127933&partnerID=8YFLogxK
U2 - 10.1007/s11886-023-01942-2
DO - 10.1007/s11886-023-01942-2
M3 - Review article
C2 - 37787858
AN - SCOPUS:85173127933
SN - 1523-3782
VL - 25
SP - 1189
EP - 1210
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 10
ER -